{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:49Z","timestamp":1792813549328,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.seminhematol.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:22:10Z","timestamp":1671772930000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Applications of virus-specific T cell therapies post-BMT"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-1975","authenticated-orcid":false,"given":"Cecilia M.","family":"Motta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS phenotypic classification for primary immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J Clin Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.12.002_bib0002","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.299.8.925","article-title":"Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases","volume":"299","author":"Burt","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.12.002_bib0003","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2018.10.049","article-title":"Virus-specific T cells: current and future use in primary immunodeficiency disorders","volume":"7","author":"Harris","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.12.002_bib0004","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2019000924","article-title":"Virus-specific T-cell therapies for patients with primary immune deficiency","volume":"135","author":"Keller","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2022.12.002_bib0005","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.12.002_bib0006","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-21-43","article-title":"Adoptive cellular immunotherapy for Epstein-Barr virus-associated lymphoproliferative disease","volume":"6","author":"Wistinghausen","year":"2022","journal-title":"Ann Lymphoma"},{"issue":"26","key":"10.1053\/j.seminhematol.2022.12.002_bib0008","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.12.002_bib0009","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0010","first-page":"120","article-title":"Adverse effects of virus-specific T-cell therapy: an integrative review","volume":"10","author":"Simmons","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2022.12.002_bib0011","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567531","article-title":"Harnessing T cells to control infections after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Basso","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.12.002_bib0013","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.ymthe.2022.02.002","article-title":"The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease","volume":"30","author":"Hont","year":"2022","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104398","article-title":"An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19","volume":"367","author":"Monzavi","year":"2021","journal-title":"Cell Immunol"},{"issue":"26","key":"10.1053\/j.seminhematol.2022.12.002_bib0015","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3389\/fimmu.2016.00393","article-title":"Comparative analysis of clinical-scale IFN-\u03b3-positive T-cell enrichment using partially and fully integrated platforms","volume":"7","author":"Priesner","year":"2016","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2008.07.017","article-title":"Rapid identification and sorting of viable virus-reactive CD4+ and CD8+ T cells based on antigen-triggered CD137 expression","volume":"339","author":"Wehler","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0019","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"issue":"16","key":"10.1053\/j.seminhematol.2022.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0021","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41409-019-0614-1","article-title":"Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction","volume":"54","author":"O'Reilly","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcyt.2020.08.006","article-title":"Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay","volume":"23","author":"Lazarski","year":"2021","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.12.002_bib0023","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.12.002_bib0024","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.12.002_bib0025","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"285","key":"10.1053\/j.seminhematol.2022.12.002_bib0026","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2022.12.002_bib0027","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"23","key":"10.1053\/j.seminhematol.2022.12.002_bib0028","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2022.12.002_bib0029","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"242","key":"10.1053\/j.seminhematol.2022.12.002_bib0030","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"285","key":"10.1053\/j.seminhematol.2022.12.002_bib0031","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0032","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.16053","article-title":"T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy","volume":"187","author":"Keller","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.12.002_bib0033","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2010-11-316745","article-title":"Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States","volume":"117","author":"Cohen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.12.002_bib0034","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"8941","key":"10.1053\/j.seminhematol.2022.12.002_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet North Am Ed"},{"issue":"19","key":"10.1053\/j.seminhematol.2022.12.002_bib0036","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/blood-2010-06-292268","article-title":"A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy","volume":"116","author":"Fox","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0037","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.12.002_bib0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jcyt.2016.06.009","article-title":"Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications","volume":"18","author":"Horlock","year":"2016","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.12.002_bib0040","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.12.002_bib0041","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.seminhematol.2022.12.002_bib0042","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.12.002_bib0043","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0044","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/bloodadvances.2020002735","article-title":"Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses","volume":"5","author":"Fabrizio","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"10.1053\/j.seminhematol.2022.12.002_bib0045","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.12.002_bib0046","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/QCO.0000000000000838","article-title":"Immunocompromised host section: adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients","volume":"35","author":"Walti","year":"2022","journal-title":"Curr Opin Infect Dis"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101539","article-title":"Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: from antiviral drugs to virus-specific T cells","volume":"71","author":"Ivana","year":"2022","journal-title":"Transpl Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-022-00497-1","article-title":"In vitro generation of BK polyomavirus-specific T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation","volume":"23","author":"Najafabadi","year":"2022","journal-title":"BMC Immunol"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.12.002_bib0049","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2020-143037","article-title":"Treatment of severe, drug-refractory viral infections with allogeneic, off-the-shelf multi-virus specific T cells in patients following HSCT: results from a phase 2 study","volume":"136","author":"Tzannou","year":"2020","journal-title":"Blood"},{"issue":"3 suppl","key":"10.1053\/j.seminhematol.2022.12.002_bib0051","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.bbmt.2018.12.546","article-title":"Hexaviral specific T-cells used for prophylaxis and treatment of viral infections in patients post stem cell transplant","volume":"25","author":"Harris","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0052","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2021-152553","article-title":"Posoleucel (ALVR105), an off-the-shelf, multivirus-specific T-cell therapy, for the prevention of viral infections post-HCT: results from an open-label cohort of a phase 2 trial","volume":"138","author":"Dadwal","year":"2021","journal-title":"Blood"},{"issue":"Pt 10","key":"10.1053\/j.seminhematol.2022.12.002_bib0053","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1099\/vir.0.82094-0","article-title":"T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus","volume":"87","author":"Li","year":"2006","journal-title":"J Gen Virol"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.12.002_bib0054","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1128\/JVI.79.17.11170-11178.2005","article-title":"Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides","volume":"79","author":"Krymskaya","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0055","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients","volume":"28","author":"Rubinstein","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1053\/j.seminhematol.2022.12.002_bib0056","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.12.002_bib0057","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.12.002_bib0058","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood.2021012249","article-title":"Cellular therapies for the treatment and prevention of SARS-CoV-2 infection","volume":"140","author":"Conway","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.12.002_bib0059","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcyt.2020.04.100","article-title":"Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies","volume":"22","author":"Cancio","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.omtm.2022.04.013","article-title":"Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products","volume":"25","author":"Durkee-Shock","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.12.002_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109432","article-title":"Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy","volume":"36","author":"Basar","year":"2021","journal-title":"Cell Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0062","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010339","article-title":"SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants","volume":"18","author":"Panikkar","year":"2022","journal-title":"PLoS Pathog"},{"issue":"25","key":"10.1053\/j.seminhematol.2022.12.002_bib0063","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood.2020008488","article-title":"SARS-CoV-2\u2013specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein","volume":"136","author":"Keller","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.12.002_bib0064","doi-asserted-by":"crossref","first-page":"S348","DOI":"10.1016\/S2666-6367(21)00448-6","article-title":"Allogeneic, off-the-shelf, Sars-Cov-2-specific T cells to treat high-risk patients with COVID-19","volume":"27","author":"Vasileiou","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"suppl 5","key":"10.1053\/j.seminhematol.2022.12.002_bib0065","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/cid\/ciu623","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"59","author":"Chemaly","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575977","article-title":"T-cell therapeutics targeting human parainfluenza virus 3 are broadly epitope specific and are cross reactive with human parainfluenza virus 1","volume":"11","author":"Harris","year":"2020","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0067","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fcimb.2020.00298","article-title":"Virus-specific T cell therapies for HIV: lessons learned from hematopoietic stem cell transplantation","volume":"10","author":"Lee","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0068","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.omtm.2019.10.001","article-title":"HIV-specific T cells can be generated against non-escaped T cell epitopes with a GMP-compliant manufacturing platform","volume":"16","author":"Patel","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0069","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.omtm.2020.08.015","article-title":"Engineered antigen-specific T cells secreting broadly neutralizing antibodies: combining innate and adaptive immune response against HIV","volume":"19","author":"Powell","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.12.002_bib0070","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic T cell\u2013resistant HIV reservoirs to elimination ex vivo","volume":"130","author":"Ren","year":"2020","journal-title":"J Clin Invest"},{"issue":"63","key":"10.1053\/j.seminhematol.2022.12.002_bib0071","first-page":"e3627","article-title":"Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus","author":"Hanley","year":"2012","journal-title":"J Vis Exp"},{"issue":"3 suppl","key":"10.1053\/j.seminhematol.2022.12.002_bib0072","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.bbmt.2019.12.591","article-title":"Third-party virus-specific T-cell infusion for treatment of refractory viral infections: interim results from PBMTC SUP1701","volume":"26","author":"Keller","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2022.12.002_bib0073","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/jco.2015.33.15_suppl.10016","article-title":"Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts","volume":"33","author":"Prockop","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.12.002_bib0074","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiz491","article-title":"Generation of norovirus-specific T cells from human donors with extensive cross-reactivity to variant sequences: implications for immunotherapy","volume":"221","author":"Hanajiri","year":"2020","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.12.002_bib0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jcyt.2019.06.008","article-title":"Generation of Zika virus\u2013specific T cells from seropositive and virus-na\u00efve donors for potential use as an autologous or \u201coff-the-shelf\u201d immunotherapeutic","volume":"21","author":"Hanajiri","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0076","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2018.206896","article-title":"Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections","volume":"105","author":"Vasileiou","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0077","first-page":"1923","article-title":"Human papillomavirus (HPV)\u2013specific T-cells can be generated from unimmunized donors for third party cell therapy of HPV-associated neoplasms","volume":"130","author":"Cruz","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0078","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","article-title":"Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation","volume":"57","author":"van der Zwan","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"10.1053\/j.seminhematol.2022.12.002_bib0079","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2022.12.002_bib0081","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \"off-the-shelf\" adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.12.002_bib0082","article-title":"Gene editing and CRISPR in the clinic: current and future perspectives","volume":"40","author":"Hirakawa Matthew","year":"2020","journal-title":"Biosci Rep"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.12.002_bib0083","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief Funct Genom"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.12.002_bib0084","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ymthe.2020.03.009","article-title":"CRISPR-edited immune effectors: the end of the beginning","volume":"28","author":"Mo","year":"2020","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0085","article-title":"Engineering T-cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","author":"Mo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0086","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41587-020-0601-5","article-title":"Engineered off-the-shelf therapeutic T cells resist host immune rejection","volume":"39","author":"Mo","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.12.002_bib0087","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol Ther"},{"issue":"23","key":"10.1053\/j.seminhematol.2022.12.002_bib0088","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","article-title":"Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)","volume":"114","author":"De Angelis","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.12.002_bib0089","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ymthe.2020.06.002","article-title":"CRISPR-Cas9-mediated glucocorticoid resistance in virus-specific T cells for adoptive T cell therapy posttransplantation","volume":"28","author":"Kaeuferle","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.12.002_bib0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2017.232","article-title":"Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT","volume":"53","author":"Qian","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1053\/j.seminhematol.2022.12.002_bib0091","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2015-08-664755","article-title":"TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells","volume":"126","author":"Menger","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0092","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2021-147274","volume":"138","author":"Prockop","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2022.12.002_bib0093","series-title":"Cell therapy: cGMP facilities and manufacturing","first-page":"161","article-title":"Commercialization of investigational cell therapy products","author":"Afrough","year":"2022"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.12.002_bib0094","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.12.002_bib0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene Ther"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.12.002_bib0096","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1-2","key":"10.1053\/j.seminhematol.2022.12.002_bib0097","first-page":"7","article-title":"Reinvigorating exhausted T cells by blockade of the PD-1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"For Immunopathol Dis Therap"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.12.002_bib0098","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.12.002_bib0099","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.12.002_bib0100","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.12.002_bib0101","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jcyt.2014.12.007","article-title":"Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood","volume":"17","author":"Hanley","year":"2015","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.12.002_bib0102","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ymthe.2018.08.015","article-title":"HIV-specific, ex vivo expanded T cell therapy: feasibility, safety, and efficacy in ART-suppressed HIV-infected individuals","volume":"26","author":"Sung","year":"2018","journal-title":"Mol Ther."}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:13Z","timestamp":1758522493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196322000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0037196322000610"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.12.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications of virus-specific T cell therapies post-BMT","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}